Total Payments
$575,752
2024 Payments
$60,469
Companies
5
Transactions
147
Medicare Patients
4,751
Medicare Billing
$579,924
Payment Breakdown by Category
Consulting$511,970 (88.9%)
Research$43,966 (7.6%)
Other$19,816 (3.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $511,970 | 129 | 88.9% |
| Unspecified | $43,966 | 5 | 7.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,816 | 13 | 3.4% |
Payments by Type
General
$531,786
142 transactions
Research
$43,966
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $361,035 | 69 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $87,195 | 52 | $0 (2021) |
| Astellas Pharma Global Development | $63,640 | 7 | $0 (2018) |
| Eli Lilly and Company | $42,166 | 4 | $0 (2024) |
| PROGENICS PHARMACEUTICALS, INC. | $21,716 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $60,469 | 16 | PFIZER INC. ($45,590) |
| 2023 | $88,575 | 14 | PFIZER INC. ($50,060) |
| 2022 | $90,968 | 18 | PFIZER INC. ($87,880) |
| 2021 | $127,960 | 25 | PFIZER INC. ($120,880) |
| 2020 | $54,680 | 24 | PFIZER INC. ($51,540) |
| 2019 | $22,940 | 20 | Merck Sharp & Dohme Corporation ($16,055) |
| 2018 | $90,265 | 20 | Astellas Pharma Global Development ($63,640) |
| 2017 | $39,895 | 10 | Merck Sharp & Dohme Corporation ($39,895) |
All Payment Transactions
147 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $5,890.00 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $175.00 | Research |
| Study: LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | ||||||
| 09/10/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,020.00 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,690.00 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,530.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2024 | PROGENICS PHARMACEUTICALS, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,104.00 | General |
| 05/07/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,020.00 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,510.00 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2024 | PROGENICS PHARMACEUTICALS, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,212.00 | General |
| 03/12/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,240.00 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $5,090.00 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $7,160.00 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,387.50 | Research |
| Study: A PHASE 2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | ||||||
| 12/19/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,060.00 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,020.00 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $4,480.00 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,650.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $1,520.00 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $6,070.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | Eli Lilly and Company | $41,991 | 3 |
| IB12B PMR ICON | Progenics Pharmaceuticals, Inc. | $1,800 | 1 |
| LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | Eli Lilly and Company | $175.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,371 | 1,442 | $2.9M | $131,814 |
| 2022 | 19 | 1,192 | 2,455 | $1.5M | $128,409 |
| 2021 | 17 | 1,190 | 2,195 | $782,304 | $154,338 |
| 2020 | 13 | 998 | 1,030 | $676,719 | $165,363 |
Total Patients
4,751
Total Services
7,122
Medicare Billing
$579,924
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 304 | 318 | $615,495 | $33,748 | 5.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 74 | 78 | $222,231 | $21,934 | 9.9% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 108 | 114 | $317,454 | $11,477 | 3.6% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Office | 2023 | 133 | 141 | $260,872 | $10,860 | 4.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 117 | 117 | $286,108 | $6,938 | 2.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 68 | 74 | $147,323 | $6,936 | 4.7% |
| 78816 | Nuclear medicine study whole body with ct scan | Facility | 2023 | 55 | 60 | $182,232 | $5,788 | 3.2% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Facility | 2023 | 66 | 70 | $143,004 | $5,292 | 3.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 62 | 65 | $143,449 | $5,142 | 3.6% |
| 78832 | Nuclear medicine study, spect imaging with concurrent ct scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days | Facility | 2023 | 44 | 50 | $30,250 | $4,225 | 14.0% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 73 | 76 | $111,296 | $3,754 | 3.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 39 | 39 | $94,515 | $2,979 | 3.2% |
| 79101 | Radioactive drug therapy through a vein | Facility | 2023 | 31 | 36 | $51,372 | $2,875 | 5.6% |
| 78813 | Nuclear medicine study whole body | Office | 2023 | 36 | 37 | $84,502 | $2,825 | 3.3% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 60 | 66 | $95,502 | $2,106 | 2.2% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 45 | 45 | $73,542 | $2,053 | 2.8% |
| 78830 | Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | Office | 2023 | 16 | 16 | $6,816 | $897.40 | 13.2% |
| 78072 | Nuclear medicine study of parathyroid with spect and ct scan | Facility | 2023 | 12 | 12 | $4,440 | $783.96 | 17.7% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 16 | 16 | $19,536 | $711.21 | 3.6% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2023 | 12 | 12 | $44,976 | $488.18 | 1.1% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Office | 2022 | 92 | 93 | $245,555 | $33,079 | 13.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 97 | 98 | $227,966 | $21,406 | 9.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 227 | 228 | $163,385 | $14,268 | 8.7% |
| 78812 | Nuclear medicine study from skull base to mid-thigh | Facility | 2022 | 179 | 179 | $133,286 | $13,024 | 9.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 29 | 29 | $36,279 | $10,837 | 29.9% |
About Dr. Yingbing Wang, MD
Dr. Yingbing Wang, MD is a Nuclear Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/13/2008. The National Provider Identifier (NPI) number assigned to this provider is 1134373384.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yingbing Wang, MD has received a total of $575,752 in payments from pharmaceutical and medical device companies, with $60,469 received in 2024. These payments were reported across 147 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($511,970).
As a Medicare-enrolled provider, Wang has provided services to 4,751 Medicare beneficiaries, totaling 7,122 services with total Medicare billing of $579,924. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Medicine
- Other Specialties Diagnostic Radiology, Diagnostic Radiology
- Location San Francisco, CA
- Active Since 11/13/2008
- Last Updated 10/24/2022
- Taxonomy Code 207U00000X
- Entity Type Individual
- NPI Number 1134373384
Products in Payments
- TALZENNA (Drug) $361,035
- KEYTRUDA (Biological) $87,195
- ENZALUTAMIDE (Drug) $63,640
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nuclear Medicine Doctors in San Francisco
Dr. Michael Dae, M.d, M.D
Nuclear Medicine — Payments: $93,000
Nuclear Medicine $93,000
Dr. Max Wu, Md, Phd, MD, PHD
Nuclear Medicine — Payments: $737.01
Nuclear Medicine $737.01
Courtney Lawhn Heath, Md, MD
Nuclear Medicine — Payments: $202.43
Nuclear Medicine $202.43
Susan Tang, Md, MD
Nuclear Medicine — Payments: $66.79
Nuclear Medicine $66.79
Dr. Eugene Morita, M.d, M.D
Nuclear Medicine
Nuclear Medicine
Dr. Gerald Schall, Md, MD
Nuclear Medicine
Nuclear Medicine